mGluR1 antagonists as therapeutic agents
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J 1 -J 4 , X, and R 1 -R 5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
1. A compound or a pharmaceutically acceptable salt or ester thereof, wherein said compound is selected from the group consisting of:
2. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt or ester thereof and at least one pharmaceutically acceptable carrier, adjuvant or vehicle.
3. The pharmaceutical composition claim 2 , further comprising one or more additional therapeutic agents.
4. The pharmaceutical composition of claim 3 , wherein said additional therapeutic agents are selected from the group consisting of therapeutic agents suitable for pain management, anti-anxiety agents, anti-migraine agents, and therapeutic agents suitable for treating urinary incontinence.
5. A compound of the formula:
or a pharmaceutically acceptable salt or ester thereof.
6. A compound of the formula;
or a pharmaceutically acceptable salt or ester thereof.
7. A compound of the formula:
or a pharmaceutically acceptable salt or ester thereof.
8. A compound of the formula:
or a pharmaceutically acceptable salt or ester thereof.
9. A compound of the formula:
or a pharmaceutically acceptable salt or ester thereof.
10. A pharmaceutical composition comprising a compound of any of claims 5 , 6 , 7 , 8 , 9 .